Pavel Sacha

Dr. Pavel Sacha

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2019 in PLOS Biology
Verified
Journal Article
Open access
PDF file
LWLieselotte Vande Walle
Lieselotte Vande Walle
ISIrma B. Stowe
Irma B. Stowe
PSPavel Sacha
Pavel Sacha
BLBettina L. Lee
Bettina L. Lee
DDDieter Demon
Dieter Demon
MLMohamed Lamkanfi
Mohamed Lamkanfi
The nucleotide-binding-domain (NBD)–and leucine-rich repeat (LRR)–containing (NLR) family, pyrin-domain–containing 3 (NLRP3) inflammasome drives pathological inflammation in a suite of autoimmune, metabolic, malignant, and neurodegenerative diseases. Additionally, NLRP3 gain-of-function point mutations cause systemic periodic fever syndromes that are collectively known as cryopyrin-associated periodic syndrome (CAPS). There is significant interest in the discovery and development of diarylsulfonylurea Cytokine Release Inhibitory Drugs (CRIDs) such as MCC950/CRID3, a potent and selective inhibitor of the NLRP3 inflammasome pathway, for the treatment of CAPS and other diseases. However, drug discovery efforts have been constrained by the lack of insight into the molecular target and mechanism by which these CRIDs inhibit the NLRP3 inflammasome pathway. Here, we show that the NAIP, CIITA, HET-E, and TP1 (NACHT) domain of NLRP3 is the molecular target of diarylsulfonylurea inhibitors. Interestingly, we find photoaffinity labeling (PAL) of the NACHT domain requires an intact (d)ATP-binding pocket and is substantially reduced for most CAPS-associated NLRP3 mutants. In concordance with this finding, MCC950/CRID3 failed to inhibit NLRP3-driven inflammatory pathology in two mouse models of CAPS. Moreover, it abolished circulating levels of interleukin (IL)-1β and IL-18 in lipopolysaccharide (LPS)-challenged wild-type mice but not in Nlrp3L351P knock-in mice and ex vivo-stimulated mutant macrophages. These results identify wild-type NLRP3 as the molecular target of MCC950/CRID3 and show that CAPS-related NLRP3 mutants escape efficient MCC950/CRID3 inhibition. Collectively, this work suggests that MCC950/CRID3-based therapies may effectively treat inflammation driven by wild-type NLRP3 but not CAPS-associated mutants.

1 February 2007 in Neuroscience
Verified
Journal Article
Closed access
PSPavel Sacha
Pavel Sacha
JZJ. Zámečník
J. Zámečník
CBCyril Bařinka
Cyril Bařinka
KHKlara Hlouchova
Klara Hlouchova
AVA. Vícha
A. Vícha
JKJan Konvalinka
Jan Konvalinka

21 January 2002 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
CBCyril Bařinka
Cyril Bařinka
MRMarkéta Rinnová
Markéta Rinnová
PSPavel Sacha
Pavel Sacha
CRCamilo Rojas
Camilo Rojas
PMPavel Majer
Pavel Majer
JKJan Konvalinka
Jan Konvalinka

5 February 2014 in Small
Verified
Journal Article
Closed access
PDF file
IRIvan Rehor
Ivan Rehor
JSJitka Slegerova
Jitka Slegerova
JKJan Kucka
Jan Kucka
VPVladimir Proks
Vladimir Proks
VPVladimira Petrakova
Vladimira Petrakova
PCPetr Cigler
Petr Cigler

1 June 2004 in Protein Science
Verified
Journal Article
Open access
PDF file
CBCyril Bařinka
Cyril Bařinka
PSPavel Sacha
Pavel Sacha
JSJan Sklenář
Jan Sklenář
PMPetr Man
Petr Man
KBKarel Bezouška
Karel Bezouška
JKJan Konvalinka
Jan Konvalinka
Glutamate carboxypeptidase II (GCPII) is a membrane peptidase expressed in the prostate, central and peripheral nervous system, kidney, small intestine, and tumor‐associated neovasculature. The GCPII form expressed in the central nervous system, termed NAALADase, is responsible for the cleavage of N‐acetylL‐aspartyl‐L‐glutamate (NAAG) yielding free glutamate in the synaptic cleft, and is implicated in various pathologic conditions associated with glutamate excitotoxicity. The prostate form of GCPII, termed prostate‐specific membrane antigen (PSMA), is up‐regulated in cancer and used as an effective prostate cancer marker. Little is known about the structure of this important pharmaceutical target. As a type II membrane protein, GCPII is heavily glycosylated. In this paper we show that N‐glycosylation is vital for proper folding and subsequent secretion of human GCPII. Analysis of the predicted N‐glycosylation sites also provides evidence that these sites are critical for GCPII carboxypeptidase activity. We confirm that all predicted N‐glycosylation sites are occupied by an oligosaccharide moiety and show that glycosylation at sites distant from the putative catalytic domain is critical for the NAAG‐hydrolyzing activity of GCPII calling the validity of previously described structural models of GCPII into question.

19 June 2025 in Medical Oncology
Verified
Journal Article
Open access
PDF file
MZMohammad Reza Zamani
Mohammad Reza Zamani
PSPavel Sacha
Pavel Sacha
Immune checkpoints are critical in modulating immune responses and maintaining self-tolerance. Cancer cells can exploit these mechanisms to evade immune detection, making immune checkpoints attractive targets for cancer therapy. The introduction of immune checkpoint inhibitors (ICIs) has transformed cancer treatment, with monoclonal antibodies targeting CTLA-4, PD-1, and PD-L1 demonstrating clinical success. However, challenges such as immune-related adverse events, primary and acquired resistance, and high treatment costs persist. To address these challenges, it is essential to explore alternative strategies, including small-molecule and peptide-based inhibitors, aptamers, RNA-based therapies, gene-editing technologies, bispecific and multispecific agents, and cell-based therapies. Additionally, innovative approaches such as lysosome-targeting chimeras, proteolysis-targeting chimeras, and N-(2-hydroxypropyl) methacrylamide copolymers are emerging as promising options for enhancing treatment effectiveness. This review highlights significant advancements in the field, focusing on their clinical implications and successes.